切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2019, Vol. 12 ›› Issue (02) : 127 -141. doi: 10.3877/cma.j.issn.1674-6902.2019.02.001

所属专题： 文献；

专家论坛

慢性阻塞性肺疾病的成因及其治疗的困惑与希望
任成山1, 王关嵩2,†(), 钱桂生2   
  1. 1. 400037　重庆，陆军军医大学（第三军医大学）新桥医院消化内科
    2. 400037　重庆，陆军军医大学（第三军医大学）新桥医院呼吸内科
  • 收稿日期:2019-02-11 出版日期:2019-04-20
  • 通信作者: 王关嵩
  • 基金资助:
    国家自然科学基金资助项目(81670047)

Nosogenesis of chronic obstructive pulmonary disease and the perplexity and hope of treatment

Chengshan Ren1, Guansong Wang2(), Guisheng Qian2   

  • Received:2019-02-11 Published:2019-04-20
  • Corresponding author: Guansong Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J]. 中华肺部疾病杂志(电子版), 2019, 12(02): 127-141.

Chengshan Ren, Guansong Wang, Guisheng Qian. Nosogenesis of chronic obstructive pulmonary disease and the perplexity and hope of treatment[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(02): 127-141.

图1 香烟烟雾初次应答导致COPD；注：TLR：Toll样受体；GM-CSF：粒细胞-巨噬细胞集落刺激因子；HSP：热休克蛋白；ICAM-1：细胞间黏附分子-1；MCP-1：单核细胞趋化蛋白-1；TNF-α：肿瘤坏死因子-α
图2 暴露于香烟烟雾后气道上皮连接的破坏；注：在香烟暴露在烟雾中，气道上皮细胞，特别是细胞间接触发生了显著变化。香烟烟雾可导致TJs的破坏，在磷酸化的ZO-1结合酪氨酸OCLN中的ZBR残留。此外，它还能降低ZO-1和OCLN的基因表达。香烟烟雾也能增加线粒体活性氧(ROS)的产生，而ROS反过来又会被激活表皮生长因子受体(EGFR)通过Src介导的ERK信号磷酸化。激活ERK可诱导TJ离解。此外，香烟烟雾还会破坏细胞与细胞之间的接触通过EGF和双调节蛋白(AREG)配体激活EGFR依赖的机制，以及EGFR独立的机制。此外，存在于香烟烟雾中的ROS可以诱导透明质酸裂解，通过其表面受体层林导致Rho激酶(岩石)磷酸化。岩石活化可以通过降低E-钙黏蛋白基因和蛋白表达来破坏AJs。AKAP：激酶锚定蛋白；CDH1：钙黏蛋白；CS：香烟；fHA：支离破碎的透明质酸；HI：透明质酸；Ub-Cbl：E3泛素连接酶。
图3 COPD与目前描述的包括哮喘在内的主要呼吸重叠综合征的中心地位的非比例维恩图，支气管扩张，纤维化和阻塞性睡眠呼吸暂停；注：慢性阻塞性肺疾病(COPD)，阻塞性睡眠呼吸暂停(OSA/OSAS)，哮喘-COPD重叠综合征、BCOS-支气管扩张症-COPD重叠综合征、FCOS-纤维化-COPD重叠综合征和OCOS-OSA-COPD重叠综合征，HRCT-高分辨率计算机断层扫描；ACOS：哮喘-COPD重叠综合征
图4 炎症微环境下启动STAT3与NF-κB的致癌作用；注：NF-κB: 核转录因子；IL-6：白细胞介素-6；COX-M: 环氧化酶；EGFR: 表皮生长因子受体；IGFR: 胰岛素样生长因子受体；VEGF: 血管内皮生长因子；HIF: 缺氧诱导因子STAT3: 信号转导与转录激活因子3；COPD：慢性阻塞性肺疾病
图5 GOLDⅠ-Ⅱ COPD患者管理治疗流程建议；注：COPD：慢性阻塞性肺疾病；ACOS或ACO：哮喘-COPD重叠综合征；LAMA：长效胆碱能拮抗剂；LABA：长效β-2受体激动剂；ICS：吸入型皮质类固醇；GOLD：全球慢性阻塞性肺疾病防治创议；mMRC dyspnea：呼吸困难量表
1
Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study[J]. Lancet, 2007, 370(9589):741-750.
2
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease[J]. Lancet, 2012, 379(9823):1341-1351.
3
任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2):104-115.
4
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary[J]. Arch Bronconeumol, 2017, 53:128-149. [PubMed:28274597]
5
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010[J]. Lancet, 2012, 380:2163-2196.
6
Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review[J]. BMC Med, 2011, 9:7.
7
World Health Organization(WHO). Burden of COPD, 2014, accessed 26 October 2015)．

URL    
8
Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections[J]. Eur Respir J, 2006, 27(2):397-412.
9
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence，and future trends[J]. Lancet, 2007, 370(9589):765-773.
10
Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study[J]. Lancet, 2007, 370(9589):741-750.
11
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2013, 380:2095-128.
12
Lin HH, Murray M, Cohen T, et al. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study[J]. Lancet, 2008, 372(9648):1473-1483.
13
Narsingam S, Bozarth AL, Abdeljalil A. Updates in the management of stable chronic obstructive pulmonary disease[J]. Postgrad Med, 2015, 127(7):758-770.
14
Kannan RR, Singh N, Przekwas A. A quasi-3D compartmental multi-scale approach to detect and quantify diseased regional lung constriction using spirometry data[J]. Int J Numer Method Biomed Eng, 2018, 34:e2973.
15
Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers[J]. Proc Am Thorac Soc, 2006, 3:218-221.
16
Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2007, 4:554-564.
17
Merrill WW. From the match to the torch: new progress against an old adversary[J]. Am J Med Sci, 2008, 335:2-6.
18
Negewo NA, Gibson PG, Mcdonald VM. COPD and its comorbidities：Impact, measurement and mechanisms[J]. Respirology, 2015, 20:1160-1171.
19
Global initial for chronic obstructive lung disease: Gloable strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report). Retrieved on August 1, 2018 at

URL    
20
DivoM, Cote C, deTorres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J]. Am. J. Respir. Crit. Care Med, 2012, 186:155-161.
21
Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities[J]. Lancet Respir. Med, 2013, 1:73-83.
22
Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly[J]. Eur. Respir. J. 2014, 44:775-788.
23
Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatorybiomarkersandexac-erbations in chronic obstructive pulmonary disease[J]. JAMA, 2013, 309:2353-2361.
24
Fu J-J, McDonald VM, Baines KJ, et al. Airway IL-1β and systemic inflammation as predictors of future exacerbation risk in asthma and COPD[J]. Chest, 2015, 148:618-29. doi: 10.1378/chest.14-2337.
25
Sohal SS, Ward C, Danial W, et al. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease[J]. Expert Rev Respir Med, 2013, 7:275-288. [PubMed:23734649]
26
Nishida K, Brune KA, Putcha N, et al. Cigarette smoke disrupts monolayer integrity by altering epithelial cell-cell adhesion and cortical tension[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 313:L581-L591. [PubMed:28642260]
27
Faner R, Sibila O, Agustí A, et al. The microbiome in respiratory medicine: current challenges and future perspectives[J]. Eur Respir J, 2017; 49:1602086. [PubMed:28404649]
28
Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go？[J]. Eur Respir Rev, 2018 September 30; 27(149):. doi：10.1183/16000617.0022-2018.
29
Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases[J]. Lancet, 2014, 384:691-702. [PubMed:25152271]
30
Heijink IH, Brandenburg SM, Postma DS, et al. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery[J]. Eur Respir J, 2012, 39:419-428.
31
McDonald VM, Higgins I, Gibson PG. Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges[J]. Drugs Aging, 2013, 30:1-17.
32
Ashley SL, Jegal Y, Moore TA, et al. gamma-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates estab-lished murine lung fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2014, 307(3):L219-230.
33
Poh TY, Mac Aogáin M, Chan AK, et al. Understanding COPD-overlap syndromes[J]. Expert Rev Respir Med, 2017, 11(4):285-298.
34
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2016, 138:16-27. [PubMed:27373322]
35
Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease[J]. N Engl J Med, 2009, 360(23):2445-2454.
36
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis，management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013, 187:347-365.
37
Aghapour M, Raee P, Moghaddam SJ, et al. Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure[J]. Am J Respir Cell Mol Biol Vol, 2018, 58(2):157-169.
38
Schamberger AC, Mise N, Jia J, et al. Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-b[J]. Am J Respir Cell Mol Biol, 2014, 50:1040-1052.
39
Heijink IH, Noordhoek JA, Timens W, et al. Abnormalities in airway epithelial junction formation in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2014, 189:1439-1442.
40
Cloonan SM, Lam HC, Ryter SW, et al. "Ciliophagy" ：the consumption of cilia components by autophagy[J]. Autophagy, 2014，10:532-534.
41
van der Toorn M, Rezayat D, Kauffman HF, et al. Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells[J]. Am J Physiol Lung Cell Mol Physiol, 2009, 297:L109-L114.
42
Oldenburger A, Poppinga WJ, Kos F, et al. A-kinase anchoring proteins contribute to loss of E-cadherin and bronchial epithelial barrier by cigarette smoke[J]. Am J Physiol Cell Physiol, 2014, 306:C585-C597.
43
Milara J, Peiró T, Serrano A, et al. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke[J]. Thorax, 2013, 68:410-420.
44
Petecchia L, Sabatini F, Varesio L, et al. Bronchial airway epithelial cell damage following exposure to cigarette smoke includes disassembly of tight junction components mediated by the extracellular signal-egulated kinase 1/2 pathway[J]. Chest, 2009, 135:1502-1512.
45
Heijink IH, van Oosterhout A, Kapus A. Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction[J]. Eur Respir J, 2010, 36:1016-1026.
46
Khan EM, Lanir R, Danielson AR, et al. Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear traffickingP[J]. FASEB J, 2008, 22:910-917.
47
Zhang L, Gallup M, Zlock L, et al. p120-catenin modulates airway epithelial cell migration induced by cigarette smoke[J]. Biochem Biophys Res Commun, 2012, 417:49-55.
48
Zhang L, Gallup M, Zlock L, et al. Rac1 and Cdc42 differentially modulate cigarette smoke-induced airway cell migration through p120-catenin-dependent and-independent pathways[J]. Am J Pathol, 2013, 182:1986-1995.
49
Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally[J]. Chest, 2010, 138:3-6.
50
Williams A, Jones JM, Ma L, et al. Pollutants from the combustion of solid biomass fuels[J]. Prog Energy Combust Sci, 2012, 38:113-137.
51
RafaelSilva, Manuel Oyarzún, Jordi Olloquequi. Pathogenic Mechanisms in Chronic Obstructive Pulmonary Disease Due to Biomass Smoke Exposure[J]. Arch Bronconeumol, 2015, 51(6):285-292.
52
Miller A. Of dung and dynein arms: understanding COPD in nonsmokers [J]. Respir Care, 2013, 58:543-545.
53
Kodgule R, Salvi S. Exposure to biomass smoke as a cause for airway disease in women and children[J]. Curr Opin Allergy Clin Immunol, 2012, 12:82-90.
54
Rosas Pérez I, Serrano J, Alfaro-Moreno E, et al. Relations between PM10 composition and cell toxicity: a multivariate and graphical approach[J]. Chemosphere, 2007, 67:1218-1228.
55
Miyata R, van Eeden SF. The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter[J]. Toxicol Appl Pharmacol, 2011, 257:209-226.
56
Eom SY, Yim DH, Moon SI, et al. Polycyclic aromatic hydrocarbon-induced oxidative stress, antioxidant capacity, and the risk of lung cancer: a pilot nested case-control study[J]. Anticancer Res, 2013, 33:3089-3097.
57
Jordi Olloquequi, Rafael Silva O. Biomass smoke as a risk factor for chronic obstructive pulmonary disease: effects on innate immunity[J]. Innate Immunity, 2016, 22(5):373-381.
58
Li MH, Fan LC, Mao B, et al. Short-term Exposure to Ambient Fine Particulate Matter Increases Hospitalizations and Mortality in COPD: A Systematic Review and Meta-analysis[J]. Chest, 2016, 149(2):447-458.
59
Gu XY, Chu X, Zeng XL, et al. Effects of PM2.5 exposure on the Notch signaling pathway and immune imbalance in chronic obstructive pulmonary disease[J]. Environ Pollut, 2017, 226:163-173.
60
刘国辉，徐永健. 重叠综合征[J]. 中国实用内科杂志，2011, 31(8):613-615.
61
World Health Organization. Chronic obstructive pulmonary disease (COPD). [cited 2016 Nov 16]. Available from:

URL    
62
To T, Zhu J, Larsen K, et al. Progression from asthma to chronic obstructive pulmonary disease. Is air pollution a risk factor？[J]. Am J Respir Crit Care Med, 2016, 194(4):429-438.
63
Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for the diagnosis, management and prevention of COPD. [cited 2017 Feb 2]. Available from:

URL    
64
Global Initiative for Asthma. 2016 GINA report, global strategy for asthma management and prevention. [cited 2016 Nov 19]. Available from:

URL    
65
Postma DS, Rabe KF. The asthma-COPD overlap syndromep[J]. N Engl J Med, 2015, 373(13):1241-1249.
66
Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities[J]. Thorax, 2009, 64(10):863-868.
67
Orie NGM SH, De Vries K, Tammeling GJ, et al. The host factor in bronchitis[J]. Bronchitis. Assen (Ed. The Netherlands: Royal Van Gorcum; 1961. p. 43-59.
68
Barnes PJ. Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases[J]. Am J Respir Crit Care Med, 2006, 174(3):240-243, 243-244.
69
Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis[J]. J Allergy Clin Immunol, 2015, 136(3):521-529.
70
Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma[J]. Respir Res, 2011, 12:127.
71
Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status[J]. Respir Med, 2013, 107(7):1053-1060.
72
Golpe R, Sanjuan Lopez P, Cano Jimenez E, et al. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke[J]. Arch Bronconeumol, 2014, 50(8):318-324.
73
Kiljander T, Helin T, Venho K, et al. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study[J]. NPJ Primary Care Respir Med, 2015, 25:15047.
74
Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion[J]. Eur Respir J, 2016, 48(3):664-673.
75
Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): a diagnostic challenge. Respirology[J]. 2016, 21(3):410-418.
76
Cosio BG, Soriano JB, López-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort[J]. Chest, 2016, 149(1):45-52.
77
Sorino C, Pedone C, Scichilone N. Fifteen-year mortality of patients with asthma-COPD overlap syndrome[J]. Eur J Intern Med, 2016, 34:72-77.
78
Lange P, Colak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis[J]. Lancet Respir Med, 2016, 4(6):454-462.
79
Caillaud D, Chanez P, Escamilla R, et al. Asthma-COPD overlap syndrome (ACOS) vs 'pure’ COPD: a distinct phenotype？[J]. Allergy, 2017, 72(1):137-145.
80
Pasteur MC, Bilton D, Hill AT. British Thoracic Society Non CFBGG. British Thoracic Society guideline for non-CF bronchiectasis[J]. Thorax, 2010, 65(7):577.
81
McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronch-iectasis[J]. Am J Respir Crit Care Med, 2013, 188(6):647-656.
82
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity[J]. Eur Respir J, 2005, 26(4):586-593.
83
Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and out-comes in combined pulmonary fibrosis and emphysema in idio-pathic pulmonary fibrosis[J]. Chest, 2013, 144(1):234-240.
84
Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults [J]. J Clin Sleep Med, 2009, 5(3):263-276.
85
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease[J]. Nat Rev Genet, 2012, 13(4):260-270.
86
Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease[J]. Mediators Inflamm. 2015; 692546:2015.
87
Chotirmall SH, Burke CM. Aging and the microbiome: implications for asthma in the elderly? [J]. Expert Rev Respir Med, 2015, 9(2):125-128.
88
Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Micro, 2017, 15(1):55-63.
89
Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers[J]. Am J Respir Crit Care Med, 2013, 187(10):1067-1075.
90
Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis[J]. Ann Am Thorac Soc, 2014, 11(4):496-503.
91
Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study[J]. Lancet Respir Med, 2014, 2(7):548-556.
92
Cameron SJ, Lewis KE, Huws SA, et al. Metagenomic sequencing of the chronic obstructive pulmonary disease upper bronchial tract microbiome reveals functional changes associated with disease severity[J]. PLoS One, 2016, 11(2):e0149095.
93
Feinstein AR.The pre-therapeutic classification of co-morbidity in chronic disease[J]. J Chronic Dis, 1970, 23(7):455-468.
94
Brandlmeier P. Multimorbidity among elderly patients in an urban general practice[J]. ZFA (Stuttgart), 1976, 52(25):1269-1275.
95
World Health Organization. The World Health Report 2008—primary health cared (now more than ever)[M]. New York: The World Health Report, 2008: 148.
96
Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD[J]. Am. J. Med, 2009, 122:348-355.
97
Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on vali-dated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease[J]. Am. J．Respir. Crit. Care Med, 2013, 187:728-735.
98
Patel ARC, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art[J]. Expert Rev. Respir. Med, 2011, 5:647-662.
99
Cafarella PA, Effing TW, Usmani Z-A, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review[J]. Respirology, 2012, 17:627-638.
100
Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs[J]. PLoS Med, 2010, 7:e1000220.
101
Decramer M, Rennard S, Troosters T, Mapel DW, et al. COPD as a lung disease with systemic consequences-clinical impact, mecha-nisms, and potential for early intervention[J]. COPD, 2008, 5:235-556.
102
Franceschi C, Campisi J. Chronicinflammation(inflammaging) and its potential contribution to age-associated diseases[J]. J．Gerontol. A. Biol Sci. Med Sci 2014, 69(Suppl. 1):S4-9.
103
Schwartz AG, Ruckdeschel JC. Familiallungcancer: geneticsus-ceptibility and relationship to chronic obstructive pulmonary disease[J]. Am. J. Respir. Crit. Care Med, 2006, 173:16-22.
104
Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD[J]. Respirology, 2011, 16:1047-1055.
105
Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease[J]. Immunol. Allergy Clin. North Am. 2003, 23:15-39.
106
Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD[J]. Chest, 2001, 119:1691-1695.
107
Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States[J]. N Engl J Med, 2013, 368:351-364.
108
Gut-Gobert C, Cavaillès A, Dixmier A, et al. Women and COPD: do we need more evidence？[J] Eur Respir Rev, 2019, doi: 10.1183/16000617.0055-2018.
109
Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries[J]. Tob Control, 1994, 3:242-247.
110
Anderson SJ, Glantz SA, Ling PM. Emotions for sale: cigarette advertising and women’s psychosocial needs[J]. Tob Control, 2005, 14:127-135.
111
Ancochea J, Miravitlles M, García-Río F, et al. Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions[J]. Arch Bronconeumol, 2013, 49:223-229.
112
Martinez CH, Raparla S, Plauschinat CA, et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease[J]. J Womens Health (Larchmt), 2012, 21:1267-1274.
113
Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007[J]. Eur Respir J, 2010, 36:758-765.
114
Tilert T, Dillon C, Paulose-Ram R, et al. Estimating the U．S. prevalence of chronic obstructive pulmonary disease using pre-and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010[J]. Respir Res, 2013, 14:103.
115
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380:2163-2196.
116
Hitchman SC, Fong GT. Gender empowerment and female-to-male smoking prevalence ratios[J]. Bull World Health Organ, 2011, 89:195-202.
117
Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China[J]. Thorax, 2007, 62:889-897.
118
Raherison C, Girodet PO. Epidemiology of COPD[J]. Eur Respir Rev, 2009, 18:213-221.
119
Raherison C, Biron E, Nocent-Ejnaini C, et al. [Are there specific characteristics of COPD in women？][J]. Rev Mal Respir, 2010, 27:611-624.
120
Spilka S, Le Nézet O, Ngantcha M, et al. Les drogues à 17 ans: analyses de l’enquête ESCAPAD 2014. Date last updated: May, 2015.

URL    
121
Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences：an update[J]. Transl Res, 2013, 162:208-218.
122
Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9:1145-1154.
123
Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema[J]. Am J Respir Crit Care Med, 2007, 176:243-252.
124
de Torres JP, Casanova C, Hernández C, et al. Gender and COPD in patients attending a pulmonary clinic[J]. Chest, 2005, 128:2012-2016.
125
Cydulka RK, Rowe BH, Clark S, et al. Gender differences in emergency department patients with chronic obstructive pulmonary disease exacerbation[J]. Acad Emeg Med, 2005, 12:1173-1179.
126
Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2000, 162:2152-2158.
127
Foreman MG, Zhang L, Murphy J, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study[J]. Am J Respir Crit Care Med, 2011, 184:414-420.
128
Sheel AW, Guenette JA, Yuan R, et al. Evidence for dysanapsis using computed tomographic imaging of the airways in older ex-smokers[J]. J Appl Physiol, 2009, 107:1622-1628.
129
Sayiner A, Hague C, Ajlan A, et al. Bronchiolitis in young female smokers [J]. Respir Med, 2013, 107:732-738.
130
Kohler M, Sandberg A, Kjellqvist S, et al. Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2013, 131:743-751.
131
Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases[J]. Biochimie, 2012, 94:2180-2189.
132
de Torres JP, Casanova C, Pinto-Plata V, et al. Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study[J]. PLoS One, 2011, 6:e16021.
133
Tam A, Morrish D, Wadsworth S, et al. The role of female hormones on lung function in chronic lung diseases[J]. BMC Womens Health, 2011, 3:11-24.
134
Wang Z., Association between chronic obstructive pulmonary disease and lung cancer: the missing link, Chin. Med. J. 126 (2013): 154-165.
135
Durham A．L., Adcock I．M., The relationship between COPD and lung cancer, Lung Cancer 90 (2015) 121-127.
136
Hashimoto N., Matsuzaki A., Okada Y., et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients, BMC Pulm. Med. 14 (2014)14.
137
Jemal A., Bray F., Center M．M., et al. Global cancer statistics, CA Cancer J. Clin. 61 (2011) 69-90.
138
Ferlay J., Soerjomataram I., Dikshit R., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer 136 (2015) E359-E386.
139
De Torres J．P., Marín J．M., Casanova C., et al. Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors, Am. J. Respir. Crit. Care Med. 184 (2011) 913-919.
140
Abal Arca J., Parente Lamelas I., Almazán Ortega R., et al. Marcos Velázquez, Lung cancer and COPD: a common combination, Arch. Bronconeumol. 45 (2009) 502-507.
141
Li Y., Swensen S．J., Karabekmez L．G., et al, Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment, Cancer Prev[J]. Res. (Phila) 4 (2011) 43-50.
142
Henschke C．I., Yip R., Boffetta P., et al. CT screening for lung cancer: importance of emphysema for never smokers and smokers, Lung Cancer 88 (2015) 42-47.
143
de Torres J．P., Wilson D．O., Sanchez-Salcedo P., et al. Lung cancer in patients with chronic obstructive pulmonary disease[J]. Development and validation of the COPD Lung Cancer Screening Score, Am. J. Respir. Crit. Care Med. 191 (2015) 285-291.
144
廖晨，余祖滨，张萍，等. 慢性阻塞性肺疾病合并肺癌122例临床特征分析 [J/CD]. 中华肺部疾病杂志(电子版)，2015, 8(1):30-34.
145
任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2):137-142.
146
Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, et al. COPD, emphysema and the onset of lung cancer[J]. A systematic review.Cancer Lett. 2016 Nov 28; 382(2):240-244.
147
Luo J., Solimini N．L., Elledge S．J.. Principles of cancer therapy: oncogene and non-oncogene addiction, Cell 136 (2009) 823-837.
148
Negrini S., Gorgoulis V．G., Halazonetis T．D., Genomic instability-an evolving hallmark of cancer, Nat. Rev. Mol. Cell Biol. 11 (2010) 220-228.
149
Agusti A., Sin D．D., Biomarkers in COPD, Clin. Chest Med. 35 (2014) 131-141.
150
Faner R., Tal-Singer R., Riley J．H., et al. Lessons from ECLIPSE: a review of COPD biomarkers, Thorax 69 (2014) 666-672.
151
Parimon T., Chien J．W., Bryson C．L., et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med. 175 (2007) 712-719.
152
Young R．P., Hopkins R．J., Christmas T., et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history, Eur. Respir. J. 34 (2009) 380-386.
153
Wess J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer [J]. Sci Transl Med, 2012, 2(62):62ra93.
154
Vermaelen K, Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPDand lung cancer [J]. Pulm Pharmacol Ther, 2013, 26(5):544-554.
155
Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease[J]. Lancet, 2009, 374:744-755.
156
Olloquequi J, Garcia-Valero J, Rodriguez E, et al. Lung CD57＋ cell density is increased in very severe COPD[J]. Histol Histopathol, 2012, 27:39-47.
157
Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? [J]. Chest, 2010, 138:3-6.
158
Baker KE, Bonvini SJ, Donovan C, et al. Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models[J]. Pulm Pharmacol Ther, 2014, 29:181-198.
159
Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial[J]. Ann Intern Med, 2009, 151:517-527.
160
van den Berge M, Steiling K, Timens W, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity[J]. Thorax, 2014, 69:14-23.
161
Milara J, Peiró T, Serrano A, et al. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD[J]. Pulm Pharmacol Ther, 2014, 28:138-148.
162
Milara J, Peiró T, Serrano A, et al. Simvastatin increases the ability of roflumilast n-oxide to inhibit cigarette smoke-induced epithelial to mesenchymal transition in well-differentiated human bronchial epithelial cells in vitro[J]. COPD, 2015, 12:320-331.
163
Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD)[J]. Am J Respir Crit Care Med, 2001, 163:1476-1483.
164
Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium[J]. Thorax, 2004, 59:992-996.
165
Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma[J]. J Allergy Clin Immunol, 2011, 128:549-556,541-512.
166
Rezaee F, DeSando SA, Ivanov AI, et al. Sustained protein kinase D activation mediates respiratory syncytial virus-induced airway barrier disruption [J]. J Virol, 2013, 87:11088-11095.
167
Gan H, Wang G, Hao Q, et al. Protein kinase D promotes airway epithelial barrier dysfunction and permeability through down-regulation of claudin-1[J]. J Biol Chem, 2013, 288:37343-37354.
168
Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary[J]. Arch Bronconeumol, 2017, 53:128-149.
169
Miravitlles M, Soler-Catalu？a JJ, Calle M, et al. Spanish guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase[J]. Arch Bronconeumol, 2017, 53(6):324-335.
170
Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2011, 10:CD005305.
171
Corhay JL, Dang DN, Van Cauwenberge H, et al. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9:27-39.
172
Jacome CIO, Marques ASPD. Pulmonary rehabilitation for mild chronic obstructive pulmonary disease: a systematic review[J]. Respir Care, 2014 Apr; 59:588-594.
173
Stoloff SW. Chron ic obstructive pu imonary di sea se megatrials: taking the result into the office practice [J]. mj Med Sci, 2010, 342(2):160-167.
174
Lareau SC, Fahy B, Meek P, et al. Chronic Obstructive Pulmonary Disease (COPD)[J]. Am J Respir Crit Care Med, 2019, 199(1):P1-P2.
175
Maleki-Yazdi MR, Singh D, Anzueto A, et al. Assessing short-term deterioration in maintenance-naive patients with copd receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials[J]. Adv Ther, 2017, 33(12):2188-2199.
176
Singh D, D′Urzo AD, Chuecos F, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol[J]. Respir Res, 2017, 18(1):106.
177
Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe[J]. Eur Respir J, 2016, 47(2):625-637.
178
Bourbeau J, Bhutani M, Hernandez P, et al. CTS position statement: pharmacotherapy in patients with COPD-an update[J]. Can J Resp Crit Care Sleep Med, 2017, 1(4):222-241.
179
O′Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance[J]. BMJ, 2010, 340:c3134.
180
Barrecheguren M, González C, Miravitlles M. What have we learned from observational studies and clinical trials of mild to moderate COPD？[J]. Respir Res, 2018, 19(1):177-188.
[1] 陈腊青, 林佳佳, 毛洪刚, 童冠海, 汪梦娜, 夏红波, 刘卓, 徐海霞, 赵玉华, 张传领. 血清细胞因子及呼出气一氧化氮在哮喘-慢性阻塞性肺疾病重叠综合征中的临床意义[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 316-320.
[2] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[3] 徐丽玲, 卢玉宝, 赵彦, 任利, 李姝艺, 符娟, 康玲, 汪青松, 尤再春. COPD管理云平台的构建及临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 481-484.
[4] 李海明, 刘鸿飞, 李俊. 血清脂蛋白酶水平与COPD患者骨骼肌质量减少的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 500-503.
[5] 周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[6] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[7] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[8] 熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[9] 王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[10] 林静, 陈芳, 刘小霞. COPD患者认知功能障碍影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 569-571.
[11] 张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[12] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[13] 廖玥, 王可, 秦江月, 吴艳秋, 陈俊, 汪涛, 文富强, 王浩. 丹龙口服液治疗轻中度慢性阻塞性肺疾病急性加重期的多中心及前瞻性研究[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 306-311.
[14] 张译梵, 张海华, 王瑛, 高贵洲, 王晓东, 屈林, 张涛. 陕西省成人慢性阻塞性肺疾病危险因素及预测模型[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 312-317.
[15] 鄢嫣, 胡娴静, 张鹤立, 李葆华. 脑卒中共病患者的共病现况及健康管理的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(03): 285-289.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号